Ehrlich ascites carcinoma.

The current investigation was delineated to find out the anticancer activity of three different formulations of Triphala and to find the best Triphala formulation for anticancer activity among the three. Aqueous extracts of Terminalia chebula, Termialia bellerica and  Phyllanthus emblica were obtained from Amruta herbals, Indore was dissolved in purified water to make Triphala 1:1:1, 1:2:3, 1:2:4 (F1, F2, F3 respectively) formulation. The number of 1x106 Ehrlich ascites carcinoma (EAC) cell was inoculated in mice. Group I served as untreated negative control while group II was considered as positive control. Group III cancerous animals received standard drug cyclophosphamide 25 mg/kg b.w., whereas group IV to VI cancerous animals were treated with F1 150, 300 and 600mg/kg b.w., group VIII to IX with F2 150, 300 and 600 mg/kg b.w and group X to XII with F3 150, 300 and 600mg/kg b.w., respectively. Different parameter such as change in body weight, determination of survival time, total ascites fluid volume, packed cell volume and haematological parameters were perceived. At the end of investigation, 6 animals from each group were immolated, blood samples were collected and WBC, RBC, Hb content was reckoned. The effect of all three formulations on reduction in body weight, tumor volume, packed cell volume, percentage increase in life span (%ILS) and haematological parameters were compared. The data revealed were suggested that all the three Triphala formulation possessed significant anticancer activity and Triphala 1:2:3 formulation at 600 mg/kg b. w., possessed maximum anticancer activity among the 9 groups compared. Key words: Triphala, Antitumor activity; Ehrlich ascites carcinoma.